Rhaeos, Inc. is a pioneer in medical device wearables for hydrocephalus, with its groundbreaking FlowSense technology designed to monitor cerebrospinal fluid shunt function rapidly and non-invasively. Developed from the world-renowned John A. Rogers Research Group at Northwestern University, the FlowSense system utilizes a small, bandage-sized patch adhered to a patient's skin over the implanted shunt tubing. This FDA breakthrough designated technology wirelessly transmits critical data on shunt functionality to a mobile app within minutes, providing clinicians with real-time information to optimize treatment plans. Rhaeos is a private medical technology company spun out of Northwestern University and is focused on developing wearable sensors to improve the care of people suffering from chronic and difficult-to-treat conditions. The company's novel FlowSense shunt monitor is a non-invasive, wireless, thermal sensor that addresses a clinical unmet need for people with hydrocephalus and is funded by the Steele Foundation for Hope, National Institute of Neurological Disorders and Stroke at the National Institutes of Health, National Science Foundation, MedTech Innovator, the Pediatric Hydrocephalus Foundation, the Southwest Pediatric Device Consortium, the National Capital Consortium for Pediatric Device Innovation, the UCSF-Stanford Pediatric Device Accelerator, the The Consortium for Technology & Innovation in Pediatrics, and public, private, and institutional investors.